Cardiodiabetology: Evolution or Revolution?

This article addresses contemporary issues in endocrine cardiology. The main content of the work is an analysis of the history of medications used in diabetology, ranging from the first animal-derived insulins to modern sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP-1 RA), which possess pronounced cardioprotective activity. Studies demonstrating their effectiveness in influencing the cardiovascular system in patients with type 2 diabetes mellitus (T2DM) are analyzed. Particular attention is paid to multicenter clinical trials that studied the effect of hypoglycemia on cardiovascular outcomes in patients with T2DM. The article also summarizes the scientific and practical experience of using SGLT2 inhibitors in patients with various cardiac arrhythmias, including those that are life-threatening for patients with T2DM.